Clinical Trial Update: Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT) [Phase 2]

View source ↗

Summary

Phase II study of Tocilizumab for glucocorticoid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Glucocorticosteroid Refractory Acute GVHD | Phase 2 | Status: TERMINATED | Results posted: 2017-09-05